Evoke Pharma (EVOK) Posts Earnings Results, Beats Estimates By $0.06 EPS

Evoke Pharma (NASDAQ:EVOK) posted its earnings results on Wednesday. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06, Bloomberg Earnings reports.

Shares of NASDAQ:EVOK opened at $3.00 on Friday. The firm has a market capitalization of $49.82 million, a P/E ratio of -3.61 and a beta of 1.35. Evoke Pharma has a 12-month low of $2.92 and a 12-month high of $3.04.

EVOK has been the topic of a number of recent research reports. Zacks Investment Research raised shares of Evoke Pharma from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a research report on Tuesday, May 8th. HC Wainwright set a $9.00 target price on shares of Evoke Pharma and gave the stock a “buy” rating in a research report on Monday, April 2nd. B. Riley reissued a “buy” rating and set a $5.00 target price (down from $10.00) on shares of Evoke Pharma in a research report on Thursday, March 8th. Finally, ValuEngine raised shares of Evoke Pharma from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $7.83.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Earnings History for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply